IP Library Granted Patent US 10,865,253
Granted Patent B2
US 10,865,253 · App. 15/536,143 · Granted Dec 15, 2020

Rodent bispecific heterodimeric proteins

Inventors: Aran F. Labrijn (Utrecht, NL); Joyce I. Meesters (Utrecht, NL); Janine Schuurman (Utrecht, NL); Paul Parren (Utrecht, NL); Anthony Armstrong (Spring House, PA); Matthew Bunce (Spring House, PA); Mark Chiu (Spring House, PA); Thomas Nesspor (Spring House, PA); Adam Zwolak (Spring House, PA)
Assignee: GENMAB A/S
C07K16/462A61K49/0008C07K16/00C07K16/2809C07K16/32C07K16/40C07K2317/21C07K2317/24C07K2317/31C07K2317/526C07K2317/64C07K2317/73
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,865,253
App. No.
15/536,143
Granted
Dec 15, 2020
Kind
B2
Abstract

Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.

Claims (21)

1. A bispecific antibody comprising first and second IgG heavy and light chain constant and variable domains (regions) wherein:

the first IgG heavy chain comprising a first Fc region, said first Fc region comprising a first CH3 domain; and

the second IgG heavy chain comprising a second Fc region, said second Fc region comprising a second CH3 domain,

wherein the first and second Fc regions originate from a rodent species, and wherein

(a) the first CH3 domain comprises at position 370 and Arg at position 409 , and

(b) the second CH3 domain comprises Leu at position 405 when using EU numbering index.

2. The bispecific antibody according to claim 1 , wherein the Fc regions are of mouse or rat origin.

3. The bispecific antibody according to claim 1 , wherein the first and second IgG heavy chains comprise variable regions that are of human origin or that are humanized variable regions.

4. The bispecific antibody according to claim 1 , wherein the first and second IgG heavy chains comprise human variable regions and rodent Fc regions.

5. The bispecific antibody according to claim 4 , wherein the rodent Fc regions are Mus musculus (mm) or Rattus norvegicus (rn) Fc regions.

6. The bispecific antibody according to claim 1 , wherein the second CH3 domain further comprises a Thr at position 411 .

7. The bispecific antibody according to claim 1 , wherein the first IgG heavy chain comprises Asp (D) at position 253 .

8. A conjugated bispecific antibody comprising the bispecific antibody according to claim 1 , wherein the second IgG heavy chain comprises Thr (T) and Leu (L) at positions 307 and/or 309 , respectively.

9. The bispecific antibody according to claim 1 , wherein said bispecific antibody is conjugated to a prodrug, peptide, drug, or a toxin.

10. The bispecific antibody according to claim 1 , wherein the first and second IgG heavy chains both comprise a CH1 region, a hinge region, a CH2 region, and a CH3 region.

11. The bispecific antibody according to claim 1 , wherein said bispecific antibody is a full-length antibody.

12. The bispecific antibody according to claim 1 , wherein

(a) the Fc region of the first IgG heavy chain is a Mus musculus (mm) or Rattus norvegicus (rn) Fc region selected from the group consisting of mmIgG1, mmIgG2a, mmIgG2b, mmIgG2c, mmIgG3, rnIgG1, rnIgG2a, rnIgG2b, and rnIgG2c, and

(b) the Fc region of the second IgG heavy chain is a Mus musculus (mm) or Rattus norvegicus (rn) Fc region selected from the group consisting of mmIgG1, mmIgG2a, mmIgG2b, mmIgG2c, mmIgG3, rnIgG1, rnIgG2a, rnIgG2b, and rnIgG2c.

13. The bispecific antibody according to claim 1 , wherein the Fc regions of both said first and said second IgG heavy chains are of the same isotype and species.

14. The bispecific antibody according to claim 1 , wherein the Fc regions of both said first and said second IgG heavy chains are of Mus musculus (mm) origin and are both of the same isotype.

Assignments (3)
SECURITY INTEREST Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 073933/0597 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 15, 2025
From: GENMAB HOLDING B.V.; GENMAB A/S; GENMAB B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 073949/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2018
From: LABRIJN, ARAN F.; MEESTERS, JOYCE I.; SCHUURMAN, JANINE; PARREN, PAUL; ARMSTRONG, ANTHONY; BUNCE, MATTHEW; CHIU, MARK; NESSPOR, THOMAS; ZWOLAK, ADAM
To: GENMAB A/S
Reel/Frame 047500/0322 →
Cited By (1)
US 12,415,859